NASDAQ:GEMP - Gemphire Therapeutics Stock Price, Forecast & News

Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."

Gemphire Therapeutics Inc (NASDAQ:GEMP) announced its quarterly earnings data on Friday, March, 15th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.15. View Gemphire Therapeutics' Earnings History.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gemphire Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gemphire Therapeutics.

News headlines about GEMP stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gemphire Therapeutics earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Gemphire Therapeutics.

Gemphire Therapeutics saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 142,800 shares, an increase of 129.2% from the November 28th total of 62,300 shares. Based on an average daily volume of 117,700 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.4% of the company's stock are short sold. View Gemphire Therapeutics' Current Options Chain.

Some companies that are related to Gemphire Therapeutics include Dynavax Technologies (DVAX), Ardelyx (ARDX), OrganiGram (OGI), CytoDyn (CYDY), Organogenesis (ORGO), Sinovac Biotech (SVA), Corbus Pharmaceuticals (CRBP), Atreca (BCEL), Rigel Pharmaceuticals (RIGL), Mirum Pharmaceuticals (MIRM), Aptorum Group (APM), Assembly Biosciences (ASMB), Mallinckrodt (MNK), Verrica Pharmaceuticals (VRCA) and Arcus Biosciences (RCUS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Gemphire Therapeutics investors own include Anavex Life Sciences (AVXL), Progenics Pharmaceuticals (PGNX), Pixelworks (PXLW), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Nektar Therapeutics (NKTR), Protalix Biotherapeutics (PLX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO) and Melinta Therapeutics (MLNT).

(GEMP) raised $30 million in an IPO on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GEMP stock can currently be purchased for approximately $8.21.

Gemphire Therapeutics has a market capitalization of $122.08 million. Gemphire Therapeutics employs 9 workers across the globe.View Additional Information About Gemphire Therapeutics.

The official website for Gemphire Therapeutics is http://www.gemphire.com/.

Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected]